Physician profile
Marc Strulowitz
NPI 1891094090
$1,503.79
in general payments reported to CMS, 2019-2025
24 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $107 · 2021: $311 · 2022: $177 · 2023: $218 · 2024: $121 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $285.28 | 2019-2021 | |
| Treace Medical Concepts, INC. | $134.89 | 2022-2025 | |
| Averitas Pharma INC. | $132.36 | 2024-2025 | Qutenza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.42 | 2021 | |
| Kerecis Limited | $84.23 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Smith+Nephew, INC. | $84.05 | 2020-2023 | Stravix Pl, Grafix, Grafix Pl |
| Organogenesis INC. | $82.24 | 2019-2021 | |
| Stryker Corporation | $67.92 | 2019-2025 | Prostep Mica, Infinity Adaptis |
| Biowound Solutions, INC. | $65.66 | 2025 | Bio-Connekt |
| Convatec INC. | $54.25 | 2023-2024 | |
| Polynovo North America LLC | $51.61 | 2022 | |
| Hartmann USA, INC. | $49.30 | 2021-2024 | Sorbalgon 4x8 5/Bx |
| Integra Lifesciences Corporation | $47.68 | 2019-2022 | |
| Grt US Holding, INC. | $45.90 | 2022 | |
| Tactile Systems Technology INC | $38.25 | 2023 | Flexitouch Plus, Entre Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.72 | 2024-2025 | Krystexxa |
| Abbvie INC. | $26.28 | 2023 | Dalvance |
| Next Science LLC | $24.61 | 2023 | Surgx, Xperience, Blastx |
| Depuy Synthes Sales INC. | $22.83 | 2025 | Motoband |
| Curonix LLC | $18.64 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Solventum Corporation | $17.31 | 2025 | Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $14.34 | 2024 | Nuzyra |
| Bioventus LLC | $14.25 | 2022 | |
| Merck Sharp & Dohme LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Strulowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.